After posting revenue growth of 39%, Repligen CEO suggests this was driven by filtration and chromatography franchises, particularly customers in gene therapy.
Biopharma industry in the US is rooted in a strong R&D sector, with the employment percentage being three times larger than the industry average, suggests PhRMA.
The newly separate business will include women’s health, legacy brands, and biosimilar units, as the main part of the business retains oncology, vaccines, hospital and animal health.
Anti-competitive actions by companies hamper uptake of biosimilars, the US FDA suggests, and announces a series of actions that will be taken against them.
Vineti’s latest financing round sees Novartis and Gilead join forces to invest in technology platform that enables scale-up of CAR Ts and allogeneic cell therapies.
The Alliance for Regenerative Medicine publishes a cross-border healthcare plan, which would enable ‘timely and effective’ access to ATMPs for patients in Europe.
Capital expenditure is rising across the pharma industry as portfolios and pipelines shift towards biologics, but the largest companies are sticking to in-house production.
The newly established deal includes the co-development of up to three T-cell therapies, by utilizing the latter’s stem-cell derived allogeneic T-cell platform.
Shortly after EMA’s approval, the US FDA follows with a positive nod for Ervebo, the first vaccine to receive approval for the prevention of Ebola virus disease.
BeiGene’s immunotherapy becomes its first treatment to receive approval in China and Boehringer announces that it has begun manufacture of the product.
With the number of roles in manufacturing projected to rise by 196% over the next five years, industry fears a lack of expertise to fill vacuum, according to survey.